A prospective trial to evaluate the effect of Imatinib, Nilotinib and Dasatinib on the pulmonary hypertension of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

Trial Profile

A prospective trial to evaluate the effect of Imatinib, Nilotinib and Dasatinib on the pulmonary hypertension of patients with chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Dasatinib; Imatinib; Nilotinib
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Pulmonary hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results of comparative analysis (n=105) presented at the 22nd Congress of the European Haematology Association.
    • 02 Feb 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top